Slide 1: Investor Relations October 30, 2024
Investor Relations October 30, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements opportunities, other expectations and ather non-historical information. Without limiting the foregoing, statements inc
Slide 3: Omnicell Investment Highlights
Investor Relations — October 30, 2024 Ominicell Investment Highlights Omnicell is positioned as a leading strategic partner to health systems in the large and growing medication management market 30+ year track record of product innovation with a strong client base of more than one-half of the top 3
Slide 4: Our Strategy
Investor Relations - October 30, 2024 Our Strategy Omnicell is transforming pharmacy care through outcomes-centric innovation combining robotics, smart devices, intelligent software, and expert services designed to optimize clinical and business outcomes across all settings of care. HEALTH SYSTEM Ce
Slide 5: Why We Believe Omnicell is Positioned to Win
Investor Relations — October 30, 2024 Why We Believe Omnicell is Positioned to Win © Y © © Omnnicell has the right Omnicell has a proven Omnicell is scaling Continued investment in solutions and the right track record of innovation Advanced Services to new products and business model to solve as the
Slide 6: The Autonomous Pharmacy
Investor Relations — October 30, 2024 The Autonomous Pharmacy Industry-Defined Vision Replace manual, error-prone activities with automated processes that are designed to be safer and more efficient. © Zero medication errors o Zero medication waste oO Zero human touches until delivery to patient © 1
Slide 7: Delivering Solutions Designed to Support Customer Operational and Economic Environments
Investor Relations — October 30, 2024 Delivering Solutions Designed to Support Customer Operational and Economic Environments CHALLENGE Errors Annually in Hospitals" Net loss for a major healthcare provider in FY '222 Pharmacists’ tasks are non-clinical Spent in compliance administration? Hospitals
Slide 8: Revenue Growth Drivers
Investor Relations — October 30, 2024 Revenue Growth Drivers Deep Customer Relationships & Robust Backlog Multiple Growth Drivers O Expansion opportunities within Oo Strong position with more existing customer base than one-half of the top 300 U.S. health systems © Robust backlog of $1143 Billion as
Slide 9: XT Amplify
XI Amplify Innovative solutions designed to maximize the value of XT technology © 2024 Omnicel Ine
Slide 10: XT Amplify
Investor Relations - October 30, 2024 XT Amplify Initial offerings in the multi-year XT Amplify innovation program XTExtend MedChill SupplyXpert ServerScale CarePlus © 2024 Omnicel, Inc 10
Slide 11: Central Med Automation Service
Investor Relations - October 30, 2024 Central Med Automation Service A powerful solution designed to ensure your pharmacy operations excel today and evolve seamlessly into the future. Transforming Pharmacy Care © 2024 Omnicel, Inc Robotics and Smart Devices Software
Slide 12: Omnicell's Suite of Advanced Services
Investor Relations — October 30, 2024 Omnicell’s Suite of Advanced Services Varying combinations of robotics, smart devices, intelligent software, and expert services that are designed to deliver outcomes in each setting of care where medications are managed Ve iN IV Compounding Central Pharmacy Car
Slide 13: Advanced Services Accelerating Advanced Services Potential
Advanced Services Accelerating Advanced Services Potential Revenue Opportunity Recurring Revenue Growth Leveraging established channels and strong customer relationships Advanced Services (% of Total Revenue) Demand driven by increasing Targeting 22% of provider digitization and need to total revenu
Slide 14: Planned New Metrics in 2025
Planned New Metrics in 2025 Connected Devices and Software Licenses Advanced Services Consumables New 2025 Metrics Connected Devices and Advanced Services Software Licenses Technical Services Consumables Our Bookings metric today includes Connected Devices and Software Licenses, Advanced Services an
Slide 15: Financial Snapshot
Investor Relations — October 30, 2024 Financial Snapshot Q3-2024 Results YoY Change % Total Revenues $282 Million -5% Non-GAAP Gross Margin % 44.5% -120 basis points Non-GAAP Operating Expenses $101 Million -8% Non-GAAP EBITDA $39 Million -5% Non-GAAP Diluted Earnings Per Share $0.56 -10% See Append
Slide 16: 2024 Guidance
2024 Guidance a Bookings! Not guided $800 Million-$875 Million Total Revenues $295-$305 Million $1100-$1.110 Billion Product Revenues $177-$182 Million $625-$630 Million Service Revenues $118-$123 Million $475-$480 Million Technical Services Revenues Not guided $236-$238 Million Advanced Services Re
Slide 17: Total Year Revenue Composition
Investor Relations — October 30, 2024 Total Year Revenue Composition Recurring Yea a Actual YoY Guidance YoY GAAP ($Million) vs Non Category (YoY) a Change % Recurring Change % Change % TY-2024 (Mid-Point) Connected Devices, Software Licenses, Non 9, 259% & Other’ Recurring Product $828 12% $623 25%
Slide 18: Backlog ($Million)
Investor Relations — October 30, 2024 Backlog! ($Million) By Type As of December 31, 2023 As of December 31, 2022 Product Backlog $6n $797 Advanced Services Backlog? $532 $418 Total Backlog $1,143 $1,215 By Duration and Type As of December 31, 2023 As of December 31, 2022 Short-Term Product Backlog
Slide 19: Strong Balance Sheet
Strong Balance Sheet $2,304M (2) As Omnicell reinvests in the transformation to $1,231M Advanced Services, Free $1,076M Cash Flow is expected $571M $554M to slow $32M Liquidity and capital Cash and Cash Equivalents Total Assets Total Equity structure support growth strategy 1.9x Investments in innov
Slide 20: A Better Way: ESG in Action
A Better Way: ESG in Action Environment Decreased Scope 1 and 2 emissions in 2023 by almost 10% from 2022 Strengthened efforts to reduce Scope 3 emissions from business travel, including emphasizing sustainable travel behaviors and offering reduced rental car rates for electric vehicles Optimized th
Slide 21: Appendix
Appendix
Slide 22: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended September 30, ‘Nine Months Ended September 30, 2024 2023 2024 2023 Reconciliation of GAAP gross profit to non-GAAP gross profit: GAAP gross profit $ 122,268 $ 131,964
Slide 23: Tax effects footnote
(a) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2024 and 2023.
Slide 24: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended September 30, ‘Nine Months Ended September 30, 2024 2023 2024 2023 Reconciliation of GAAP net income (loss) per share - diluted to non-GAAP net income per share - dilu
Slide 25: Reconciliation of GAAP net income (loss) to non-GAAP EBITDA
Reconciliation of GAAP net income (loss) to non-GAAP EBITDA“: GAAP net income (loss) Share-based compensation expense Interest (income) and expense, net Depreciation and amortization expense Acquisition accounting impact related to deferred revenues Acquisition-related expenses Impairment and abando
Slide 26: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage)
Slide 27: Slide 27